RIPK1 and neoplasm: Sulkshane et al. [279] demonstrated that Obatoclax (GX15-070), a Bcl-2 antagonist, promoted necroptosis in in vitro and in vivo oral cancer models and in rhabdomyosarcoma cells via recruiting the RIPK1/-3/MLKL complex onto the autophagosome membrane, resulting in tumor growth suppression in these cancer models.